Human
Longevity
Biotechnology
Born out of the scientific field of biogerontology, NOVOS Bio focuses on modalities that track and slow the aging process, while extending healthspan and lifespan.
About
Our Mission
At NOVOS Bio’s mission is to disrupt humanity’s concept of aging by developing cutting-edge biotechnologies, tests, and therapies that significantly slow it down and extend healthy lifespan.
Maximizing Lives
NOVOS Bio spans a range of groundbreaking solutions designed to target the fundamental mechanisms of aging. From advanced bioinformatics and AI, drug screening, to nutraceuticals for consumers, our research-driven approach is at the forefront of the longevity revolution, offering people the tools they need to optimize their health and well-being today and for decades to come.
Drug Discovery
We conduct in-vitro and in-vivo studies on novel compounds and combinations, with an emphasis on natural molecules.
Bioinformatics & AI
Leaders in bioinformatics, machine learning, and Omic sciences, including epigenetics, proteomics, lipidomics, and metabolomics.
Digital Applications
Committed to public health, we offer free & accessible AI-based digital tools that assist people with slowing their aging, like FaceAge & NOVOS Life
Thought Leadership
Our team regularly publishes scientific papers, speaks at events across the world, and is featured in top tier publications and documentaries.
Consultation & Advisory
We have advised and collaborated with the world’s top 100 hospitals, Fortune 500 consumer brands, and top-tier luxury hospitality venues.
Consumer
NOVOS Labs is our consumer arm–a global leader in the field–offering university-studied patent-pending formulations, biological age tests & digital tools.
Contact
We welcome inquiries from those interested in exploring the frontiers of longevity in research collaborations, commercial partnerships, and increasing public awareness.
Team
NOVOS Bio’s team of experts and advisors spans the scientific field of biogerontology and longevity research, from genetics and epigenetics, to growth pathways, novel molecules, animal & human research, human disease, machine learning, and more.
Dr. George Church, PhD
Harvard Medical School
Massachusetts Institute of Technology
Dr. Pamela Maher
University of British Columbia
Salk Institute for Biological Studies
Dr. Joao Pedro Magalhaes
Harvard Medical School
University of Birmingham
Dr. Oliver Medvedik, PhD
Harvard Medical School
Dr. Avi Rosenbaum, PhD
Harvard Medical School
Dr. Robert Lufkin, MD
USC School of Medicine
Dr. Matt Kaeberlein, PhD
Massachusetts Institute of Technology
University of Washington
Dr. Diogo Barardo, PhD
Director of R&D, NOVOS Bio
National University of Singapore
Christopher Mirabile
Founder, CEO
New York University
Press
Affiliations
NOVOS Bio is a member of the Longevity Biotechnology Association.
NOVOS Bio’s approach to aging was recognized by the X Prize Healthspan competition, after being selected as a team to compete in the seven year, $101 million healthspan competition.
